SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Opko Health, Inc. – ‘10-Q’ for 3/31/16 – ‘EX-32.1’

On:  Monday, 5/9/16, at 4:27pm ET   ·   For:  3/31/16   ·   Accession #:  944809-16-22   ·   File #:  1-33528

Previous ‘10-Q’:  ‘10-Q’ on 11/9/15 for 9/30/15   ·   Next:  ‘10-Q’ on 8/8/16 for 6/30/16   ·   Latest:  ‘10-Q’ on 11/6/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/09/16  Opko Health, Inc.                 10-Q        3/31/16   77:8.6M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    593K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
12: R1          Document and Entity Information                     HTML     41K 
13: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML    105K 
14: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     31K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML     91K 
                (Unaudited)                                                      
16: R5          Condensed Consolidated Statements of Comprehensive  HTML     44K 
                Loss (Unaudited)                                                 
17: R6          Condensed Consolidated Statements of Cash Flows     HTML    134K 
                (Unaudited)                                                      
18: R7          Condensed Consolidated Statements of Cash Flows     HTML     25K 
                (Unaudited) (Parenthetical)                                      
19: R8          Business and Organization                           HTML     33K 
20: R9          Summary of Significant Accounting Policies          HTML     76K 
21: R10         Earnings (Loss) Per Share                           HTML     29K 
22: R11         Composition of Certain Financial Statement          HTML    130K 
                Captions                                                         
23: R12         Acquisitions, Investments and Licenses              HTML    116K 
24: R13         Debt                                                HTML    131K 
25: R14         Accumulated Other Comprehensive Income (Loss)       HTML     38K 
26: R15         Fair Value Measurements                             HTML    145K 
27: R16         Derivative Contracts                                HTML     53K 
28: R17         Related Party Transactions                          HTML     32K 
29: R18         Commitments and Contingencies                       HTML     36K 
30: R19         Strategic Alliances                                 HTML     43K 
31: R20         Segments                                            HTML    104K 
32: R21         Subsequent Events                                   HTML     34K 
33: R22         Summary of Significant Accounting Policies          HTML    132K 
                (Policies)                                                       
34: R23         Composition of Certain Financial Statement          HTML    131K 
                Captions (Tables)                                                
35: R24         Acquisitions, Investments and Licenses (Tables)     HTML     90K 
36: R25         Debt (Tables)                                       HTML    114K 
37: R26         Accumulated Other Comprehensive Income (Loss)       HTML     35K 
                (Tables)                                                         
38: R27         Fair Value Measurements (Tables)                    HTML    143K 
39: R28         Derivative Contracts (Tables)                       HTML     48K 
40: R29         Segments (Tables)                                   HTML     97K 
41: R30         Business and Organization (Details)                 HTML     48K 
42: R31         Summary of Significant Accounting Policies          HTML     97K 
                (Details)                                                        
43: R32         Earnings (Loss) Per Share (Details)                 HTML     34K 
44: R33         Composition of Certain Financial Statement          HTML    143K 
                Captions (Details)                                               
45: R34         Composition of Certain Financial Statement          HTML     61K 
                Captions - Changes in Goodwill (Details)                         
46: R35         Acquisitions, Investments and Licenses -            HTML     78K 
                Acquisition Narrative (Details)                                  
47: R36         Acquisitions, Investments and Licenses -            HTML     84K 
                Bio-Reference Purchase Price Allocation (Details)                
48: R37         Acquisitions, Investments and Licenses - Schedule   HTML     32K 
                of Pro Forma (Details)                                           
49: R38         Acquisitions, Investments and Licenses - EirGen     HTML     63K 
                Purchase Price Allocation (Details)                              
50: R39         Acquisitions, Investments and Licenses - Summary    HTML     36K 
                of Investments (Details)                                         
51: R40         Acquisitions, Investments and Licenses - Equity     HTML     52K 
                Method Investments Narrative (Details)                           
52: R41         Acquisitions, Investments and Licenses - Available  HTML     47K 
                for Sale Investments, Sale of Investments and                    
                Warrants and Options Narrative (Details)                         
53: R42         Acquisitions, Investments and Licenses - Variable   HTML     60K 
                Interest Entities Narrative (Details)                            
54: R43         Acquisitions, Investments and Licenses - Other      HTML     49K 
                Narrative (Details)                                              
55: R44         Debt - Narrative (Details)                          HTML    144K 
56: R45         Debt - Notes (Details)                              HTML     58K 
57: R46         Debt - Inputs Used In Lattice Model (Details)       HTML     41K 
58: R47         Debt - Fair Value Of Embedded Derivatives           HTML     29K 
                (Details)                                                        
59: R48         Debt - Lines Of Credit (Details)                    HTML     60K 
60: R49         Debt - Mortgage Notes And Other Debt (Details)      HTML     32K 
61: R50         Accumulated Other Comprehensive Income (Loss)       HTML     37K 
                (Details)                                                        
62: R51         Fair Value Measurements - Summary Of Investments    HTML     36K 
                (Details)                                                        
63: R52         Fair Value Measurements - Assets And Liabilities    HTML     60K 
                Measured At Fair Value (Details)                                 
64: R53         Fair Value Measurements - Notes (Details)           HTML     29K 
65: R54         Fair Value Measurements - Level 3 Reconciliation    HTML     38K 
                (Details)                                                        
66: R55         Fair Value Measurements - Narrative (Details)       HTML     34K 
67: R56         Derivative Contracts - Balance Sheet Component      HTML     40K 
                (Details)                                                        
68: R57         Derivative Contracts - Derivative Gains (Losses)    HTML     32K 
                (Details)                                                        
69: R58         Related Party Transactions (Details)                HTML    111K 
70: R59         Commitments and Contingencies (Details)             HTML     37K 
71: R60         Strategic Alliances (Details)                       HTML     96K 
72: R61         Segments - Narrative (Details)                      HTML     42K 
73: R62         Segments - Operations and Assets Information        HTML     74K 
                (Details)                                                        
74: R63         Subsequent Events (Details)                         HTML     63K 
76: XML         IDEA XML File -- Filing Summary                      XML    136K 
75: EXCEL       IDEA Workbook of Financial Reports                  XLSX    108K 
 6: EX-101.INS  XBRL Instance -- opk-20160331                        XML   2.50M 
 8: EX-101.CAL  XBRL Calculations -- opk-20160331_cal                XML    234K 
 9: EX-101.DEF  XBRL Definitions -- opk-20160331_def                 XML   1.06M 
10: EX-101.LAB  XBRL Labels -- opk-20160331_lab                      XML   2.02M 
11: EX-101.PRE  XBRL Presentations -- opk-20160331_pre               XML   1.28M 
 7: EX-101.SCH  XBRL Schema -- opk-20160331                          XSD    190K 
77: ZIP         XBRL Zipped Folder -- 0000944809-16-000022-xbrl      Zip    296K 


‘EX-32.1’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  


Exhibit 32.1
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Frost, Chief Executive Officer of OPKO Health, Inc. (the “Company”), hereby certify that:
The Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
 
Chief Executive Officer




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:5/9/168-K
For Period end:3/31/164
 List all Filings 
Top
Filing Submission 0000944809-16-000022   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 10:49:07.1am ET